A 90-day study of sub-chronic oral toxicity of 20 nm positively charged zinc oxide nanoparticles in Sprague Dawley rats
The study reported here was conducted to determine the systemic oral toxicity and to find the no-observed-adverse-effect level of 20 nm positively charged zinc oxide (ZnO(SM20(+))) nanoparticles in Sprague Dawley rats for 90 days. For the 90-day toxicity study, the high dose was set as 500 mg per kg...
Gespeichert in:
Veröffentlicht in: | International journal of nanomedicine 2014, Vol.9 Suppl 2 (2), p.93-107 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 107 |
---|---|
container_issue | 2 |
container_start_page | 93 |
container_title | International journal of nanomedicine |
container_volume | 9 Suppl 2 |
creator | Park, Hark-Soo Kim, Seon-Ju Lee, Taek-Jin Kim, Geon-Yong Meang, EunHo Hong, Jeong-Sup Kim, Su-Hyon Koh, Sang-Bum Hong, Seung-Guk Sun, Yle-Shik Kang, Jin Seok Kim, Yu-Ri Kim, Meyoung-Kon Jeong, Jayoung Lee, Jong-Kwon Son, Woo-Chan Park, Jae-Hak |
description | The study reported here was conducted to determine the systemic oral toxicity and to find the no-observed-adverse-effect level of 20 nm positively charged zinc oxide (ZnO(SM20(+))) nanoparticles in Sprague Dawley rats for 90 days.
For the 90-day toxicity study, the high dose was set as 500 mg per kg of body weight (mg/kg) and the middle and low dose were set to 250 mg/kg and 125 mg/kg, respectively. The rats were held for a 14-day recovery period after the last administration, to observe for the persistence or reduction of any toxic effects. A distributional study was also carried out for the systemic distribution of ZnO(SM20(+)) NPs.
No rats died during the test period. There were no significant clinical changes due to the test article during the experimental period in functional assessment, body weight, food and water consumption, ophthalmological testing, urine analysis, necropsy findings, or organ weights, but salivation was observed immediately after administration in both sexes. The total red blood cell count was increased, and hematocrit, albumin, mean cell volume, mean cell hemoglobin, and mean cell hemoglobin concentration were decreased significantly compared with control in both 500 mg/kg groups. Total protein and albumin levels were decreased significantly in both sexes in the 250 and 500 mg/kg groups. Histopathological studies revealed acinar cell apoptosis in the pancreas, inflammation and edema in stomach mucosa, and retinal atrophy of the eye in the 500 mg/kg group.
There were significant parameter changes in terms of anemia in the hematological and blood chemical analyses in the 250 and 500 mg/kg groups. The significant toxic change was observed to be below 125 mg/kg, so the no-observed-adverse-effect level was not determined, but the lowest-observed-adverse-effect level was considered to be 125 mg/kg in both sexes and the target organs were found to be the pancreas, eye, and stomach. |
doi_str_mv | 10.2147/IJN.S57927 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1647009330</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A401216703</galeid><sourcerecordid>A401216703</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-cb815d5ab9a1f6f0572e7fc961607c112ff7ccd96482dee5c63392dbd33b9e63</originalsourceid><addsrcrecordid>eNqN0U1vFCEYB3BibGxdvfgBDIkXYzIrLzswHDe1aptGD-19wsDDFjMDIzBtp5_eWbcaTTwYDhD4PU-AP0KvKFkzupHvzy--rK9qqZh8gk4olU3FCOVP_1gfo-c5fyOklo1Qz9Axq2tRN0ydoLstVqSyesa5THbG0eE8dZW5STF4g2PSPS7x3htffh4ygsOAx5h98bfQz9jc6LQDix98WPi9t4CDDnHUqXjTQ8Y-4Ksx6d0E-IO-62HGSZf8Ah053Wd4-Tiv0PXHs-vTz9Xl10_np9vLyvBGlsp0Da1trTulqRNueQAD6YwSVBBpKGXOSWOsEpuGWYDaCM4Vs53lvFMg-Aq9PbQdU_w-QS7t4LOBvtcB4pRbKjaSEMU5-R-6fB9nC16hNwe60z20PrhYkjZ73m43hDIqJNmr9T_UMiwM3sQAzi_7fxW8OxSYFHNO4Nox-UGnuaWk3SfdLkm3h6QX_PrxulM3gP1Nf0XLfwDKuqIB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1645783293</pqid></control><display><type>article</type><title>A 90-day study of sub-chronic oral toxicity of 20 nm positively charged zinc oxide nanoparticles in Sprague Dawley rats</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Dove Press Free</source><source>Free E-Journal (出版社公開部分のみ)</source><source>PubMed</source><source>PubMed Central Open Access</source><creator>Park, Hark-Soo ; Kim, Seon-Ju ; Lee, Taek-Jin ; Kim, Geon-Yong ; Meang, EunHo ; Hong, Jeong-Sup ; Kim, Su-Hyon ; Koh, Sang-Bum ; Hong, Seung-Guk ; Sun, Yle-Shik ; Kang, Jin Seok ; Kim, Yu-Ri ; Kim, Meyoung-Kon ; Jeong, Jayoung ; Lee, Jong-Kwon ; Son, Woo-Chan ; Park, Jae-Hak</creator><creatorcontrib>Park, Hark-Soo ; Kim, Seon-Ju ; Lee, Taek-Jin ; Kim, Geon-Yong ; Meang, EunHo ; Hong, Jeong-Sup ; Kim, Su-Hyon ; Koh, Sang-Bum ; Hong, Seung-Guk ; Sun, Yle-Shik ; Kang, Jin Seok ; Kim, Yu-Ri ; Kim, Meyoung-Kon ; Jeong, Jayoung ; Lee, Jong-Kwon ; Son, Woo-Chan ; Park, Jae-Hak</creatorcontrib><description>The study reported here was conducted to determine the systemic oral toxicity and to find the no-observed-adverse-effect level of 20 nm positively charged zinc oxide (ZnO(SM20(+))) nanoparticles in Sprague Dawley rats for 90 days.
For the 90-day toxicity study, the high dose was set as 500 mg per kg of body weight (mg/kg) and the middle and low dose were set to 250 mg/kg and 125 mg/kg, respectively. The rats were held for a 14-day recovery period after the last administration, to observe for the persistence or reduction of any toxic effects. A distributional study was also carried out for the systemic distribution of ZnO(SM20(+)) NPs.
No rats died during the test period. There were no significant clinical changes due to the test article during the experimental period in functional assessment, body weight, food and water consumption, ophthalmological testing, urine analysis, necropsy findings, or organ weights, but salivation was observed immediately after administration in both sexes. The total red blood cell count was increased, and hematocrit, albumin, mean cell volume, mean cell hemoglobin, and mean cell hemoglobin concentration were decreased significantly compared with control in both 500 mg/kg groups. Total protein and albumin levels were decreased significantly in both sexes in the 250 and 500 mg/kg groups. Histopathological studies revealed acinar cell apoptosis in the pancreas, inflammation and edema in stomach mucosa, and retinal atrophy of the eye in the 500 mg/kg group.
There were significant parameter changes in terms of anemia in the hematological and blood chemical analyses in the 250 and 500 mg/kg groups. The significant toxic change was observed to be below 125 mg/kg, so the no-observed-adverse-effect level was not determined, but the lowest-observed-adverse-effect level was considered to be 125 mg/kg in both sexes and the target organs were found to be the pancreas, eye, and stomach.</description><identifier>ISSN: 1178-2013</identifier><identifier>ISSN: 1176-9114</identifier><identifier>EISSN: 1178-2013</identifier><identifier>DOI: 10.2147/IJN.S57927</identifier><identifier>PMID: 25565829</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Administration, Oral ; Animals ; Apoptosis - drug effects ; Cations ; Edema ; Metal Nanoparticles - administration & dosage ; Metal Nanoparticles - chemistry ; Metal Nanoparticles - toxicity ; Nanoparticles ; Pancreas - drug effects ; Particle Size ; Physiological aspects ; Properties ; Rats ; Rats, Sprague-Dawley ; Tissue Distribution ; Toxicity Tests, Subchronic ; Zinc oxide ; Zinc Oxide - administration & dosage ; Zinc Oxide - chemistry ; Zinc Oxide - pharmacokinetics ; Zinc Oxide - toxicity</subject><ispartof>International journal of nanomedicine, 2014, Vol.9 Suppl 2 (2), p.93-107</ispartof><rights>COPYRIGHT 2014 Dove Medical Press Limited</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-cb815d5ab9a1f6f0572e7fc961607c112ff7ccd96482dee5c63392dbd33b9e63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,3849,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25565829$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Hark-Soo</creatorcontrib><creatorcontrib>Kim, Seon-Ju</creatorcontrib><creatorcontrib>Lee, Taek-Jin</creatorcontrib><creatorcontrib>Kim, Geon-Yong</creatorcontrib><creatorcontrib>Meang, EunHo</creatorcontrib><creatorcontrib>Hong, Jeong-Sup</creatorcontrib><creatorcontrib>Kim, Su-Hyon</creatorcontrib><creatorcontrib>Koh, Sang-Bum</creatorcontrib><creatorcontrib>Hong, Seung-Guk</creatorcontrib><creatorcontrib>Sun, Yle-Shik</creatorcontrib><creatorcontrib>Kang, Jin Seok</creatorcontrib><creatorcontrib>Kim, Yu-Ri</creatorcontrib><creatorcontrib>Kim, Meyoung-Kon</creatorcontrib><creatorcontrib>Jeong, Jayoung</creatorcontrib><creatorcontrib>Lee, Jong-Kwon</creatorcontrib><creatorcontrib>Son, Woo-Chan</creatorcontrib><creatorcontrib>Park, Jae-Hak</creatorcontrib><title>A 90-day study of sub-chronic oral toxicity of 20 nm positively charged zinc oxide nanoparticles in Sprague Dawley rats</title><title>International journal of nanomedicine</title><addtitle>Int J Nanomedicine</addtitle><description>The study reported here was conducted to determine the systemic oral toxicity and to find the no-observed-adverse-effect level of 20 nm positively charged zinc oxide (ZnO(SM20(+))) nanoparticles in Sprague Dawley rats for 90 days.
For the 90-day toxicity study, the high dose was set as 500 mg per kg of body weight (mg/kg) and the middle and low dose were set to 250 mg/kg and 125 mg/kg, respectively. The rats were held for a 14-day recovery period after the last administration, to observe for the persistence or reduction of any toxic effects. A distributional study was also carried out for the systemic distribution of ZnO(SM20(+)) NPs.
No rats died during the test period. There were no significant clinical changes due to the test article during the experimental period in functional assessment, body weight, food and water consumption, ophthalmological testing, urine analysis, necropsy findings, or organ weights, but salivation was observed immediately after administration in both sexes. The total red blood cell count was increased, and hematocrit, albumin, mean cell volume, mean cell hemoglobin, and mean cell hemoglobin concentration were decreased significantly compared with control in both 500 mg/kg groups. Total protein and albumin levels were decreased significantly in both sexes in the 250 and 500 mg/kg groups. Histopathological studies revealed acinar cell apoptosis in the pancreas, inflammation and edema in stomach mucosa, and retinal atrophy of the eye in the 500 mg/kg group.
There were significant parameter changes in terms of anemia in the hematological and blood chemical analyses in the 250 and 500 mg/kg groups. The significant toxic change was observed to be below 125 mg/kg, so the no-observed-adverse-effect level was not determined, but the lowest-observed-adverse-effect level was considered to be 125 mg/kg in both sexes and the target organs were found to be the pancreas, eye, and stomach.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Apoptosis - drug effects</subject><subject>Cations</subject><subject>Edema</subject><subject>Metal Nanoparticles - administration & dosage</subject><subject>Metal Nanoparticles - chemistry</subject><subject>Metal Nanoparticles - toxicity</subject><subject>Nanoparticles</subject><subject>Pancreas - drug effects</subject><subject>Particle Size</subject><subject>Physiological aspects</subject><subject>Properties</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Tissue Distribution</subject><subject>Toxicity Tests, Subchronic</subject><subject>Zinc oxide</subject><subject>Zinc Oxide - administration & dosage</subject><subject>Zinc Oxide - chemistry</subject><subject>Zinc Oxide - pharmacokinetics</subject><subject>Zinc Oxide - toxicity</subject><issn>1178-2013</issn><issn>1176-9114</issn><issn>1178-2013</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0U1vFCEYB3BibGxdvfgBDIkXYzIrLzswHDe1aptGD-19wsDDFjMDIzBtp5_eWbcaTTwYDhD4PU-AP0KvKFkzupHvzy--rK9qqZh8gk4olU3FCOVP_1gfo-c5fyOklo1Qz9Axq2tRN0ydoLstVqSyesa5THbG0eE8dZW5STF4g2PSPS7x3htffh4ygsOAx5h98bfQz9jc6LQDix98WPi9t4CDDnHUqXjTQ8Y-4Ksx6d0E-IO-62HGSZf8Ah053Wd4-Tiv0PXHs-vTz9Xl10_np9vLyvBGlsp0Da1trTulqRNueQAD6YwSVBBpKGXOSWOsEpuGWYDaCM4Vs53lvFMg-Aq9PbQdU_w-QS7t4LOBvtcB4pRbKjaSEMU5-R-6fB9nC16hNwe60z20PrhYkjZ73m43hDIqJNmr9T_UMiwM3sQAzi_7fxW8OxSYFHNO4Nox-UGnuaWk3SfdLkm3h6QX_PrxulM3gP1Nf0XLfwDKuqIB</recordid><startdate>2014</startdate><enddate>2014</enddate><creator>Park, Hark-Soo</creator><creator>Kim, Seon-Ju</creator><creator>Lee, Taek-Jin</creator><creator>Kim, Geon-Yong</creator><creator>Meang, EunHo</creator><creator>Hong, Jeong-Sup</creator><creator>Kim, Su-Hyon</creator><creator>Koh, Sang-Bum</creator><creator>Hong, Seung-Guk</creator><creator>Sun, Yle-Shik</creator><creator>Kang, Jin Seok</creator><creator>Kim, Yu-Ri</creator><creator>Kim, Meyoung-Kon</creator><creator>Jeong, Jayoung</creator><creator>Lee, Jong-Kwon</creator><creator>Son, Woo-Chan</creator><creator>Park, Jae-Hak</creator><general>Dove Medical Press Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>2014</creationdate><title>A 90-day study of sub-chronic oral toxicity of 20 nm positively charged zinc oxide nanoparticles in Sprague Dawley rats</title><author>Park, Hark-Soo ; Kim, Seon-Ju ; Lee, Taek-Jin ; Kim, Geon-Yong ; Meang, EunHo ; Hong, Jeong-Sup ; Kim, Su-Hyon ; Koh, Sang-Bum ; Hong, Seung-Guk ; Sun, Yle-Shik ; Kang, Jin Seok ; Kim, Yu-Ri ; Kim, Meyoung-Kon ; Jeong, Jayoung ; Lee, Jong-Kwon ; Son, Woo-Chan ; Park, Jae-Hak</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-cb815d5ab9a1f6f0572e7fc961607c112ff7ccd96482dee5c63392dbd33b9e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Apoptosis - drug effects</topic><topic>Cations</topic><topic>Edema</topic><topic>Metal Nanoparticles - administration & dosage</topic><topic>Metal Nanoparticles - chemistry</topic><topic>Metal Nanoparticles - toxicity</topic><topic>Nanoparticles</topic><topic>Pancreas - drug effects</topic><topic>Particle Size</topic><topic>Physiological aspects</topic><topic>Properties</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Tissue Distribution</topic><topic>Toxicity Tests, Subchronic</topic><topic>Zinc oxide</topic><topic>Zinc Oxide - administration & dosage</topic><topic>Zinc Oxide - chemistry</topic><topic>Zinc Oxide - pharmacokinetics</topic><topic>Zinc Oxide - toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Hark-Soo</creatorcontrib><creatorcontrib>Kim, Seon-Ju</creatorcontrib><creatorcontrib>Lee, Taek-Jin</creatorcontrib><creatorcontrib>Kim, Geon-Yong</creatorcontrib><creatorcontrib>Meang, EunHo</creatorcontrib><creatorcontrib>Hong, Jeong-Sup</creatorcontrib><creatorcontrib>Kim, Su-Hyon</creatorcontrib><creatorcontrib>Koh, Sang-Bum</creatorcontrib><creatorcontrib>Hong, Seung-Guk</creatorcontrib><creatorcontrib>Sun, Yle-Shik</creatorcontrib><creatorcontrib>Kang, Jin Seok</creatorcontrib><creatorcontrib>Kim, Yu-Ri</creatorcontrib><creatorcontrib>Kim, Meyoung-Kon</creatorcontrib><creatorcontrib>Jeong, Jayoung</creatorcontrib><creatorcontrib>Lee, Jong-Kwon</creatorcontrib><creatorcontrib>Son, Woo-Chan</creatorcontrib><creatorcontrib>Park, Jae-Hak</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>International journal of nanomedicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Hark-Soo</au><au>Kim, Seon-Ju</au><au>Lee, Taek-Jin</au><au>Kim, Geon-Yong</au><au>Meang, EunHo</au><au>Hong, Jeong-Sup</au><au>Kim, Su-Hyon</au><au>Koh, Sang-Bum</au><au>Hong, Seung-Guk</au><au>Sun, Yle-Shik</au><au>Kang, Jin Seok</au><au>Kim, Yu-Ri</au><au>Kim, Meyoung-Kon</au><au>Jeong, Jayoung</au><au>Lee, Jong-Kwon</au><au>Son, Woo-Chan</au><au>Park, Jae-Hak</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A 90-day study of sub-chronic oral toxicity of 20 nm positively charged zinc oxide nanoparticles in Sprague Dawley rats</atitle><jtitle>International journal of nanomedicine</jtitle><addtitle>Int J Nanomedicine</addtitle><date>2014</date><risdate>2014</risdate><volume>9 Suppl 2</volume><issue>2</issue><spage>93</spage><epage>107</epage><pages>93-107</pages><issn>1178-2013</issn><issn>1176-9114</issn><eissn>1178-2013</eissn><abstract>The study reported here was conducted to determine the systemic oral toxicity and to find the no-observed-adverse-effect level of 20 nm positively charged zinc oxide (ZnO(SM20(+))) nanoparticles in Sprague Dawley rats for 90 days.
For the 90-day toxicity study, the high dose was set as 500 mg per kg of body weight (mg/kg) and the middle and low dose were set to 250 mg/kg and 125 mg/kg, respectively. The rats were held for a 14-day recovery period after the last administration, to observe for the persistence or reduction of any toxic effects. A distributional study was also carried out for the systemic distribution of ZnO(SM20(+)) NPs.
No rats died during the test period. There were no significant clinical changes due to the test article during the experimental period in functional assessment, body weight, food and water consumption, ophthalmological testing, urine analysis, necropsy findings, or organ weights, but salivation was observed immediately after administration in both sexes. The total red blood cell count was increased, and hematocrit, albumin, mean cell volume, mean cell hemoglobin, and mean cell hemoglobin concentration were decreased significantly compared with control in both 500 mg/kg groups. Total protein and albumin levels were decreased significantly in both sexes in the 250 and 500 mg/kg groups. Histopathological studies revealed acinar cell apoptosis in the pancreas, inflammation and edema in stomach mucosa, and retinal atrophy of the eye in the 500 mg/kg group.
There were significant parameter changes in terms of anemia in the hematological and blood chemical analyses in the 250 and 500 mg/kg groups. The significant toxic change was observed to be below 125 mg/kg, so the no-observed-adverse-effect level was not determined, but the lowest-observed-adverse-effect level was considered to be 125 mg/kg in both sexes and the target organs were found to be the pancreas, eye, and stomach.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>25565829</pmid><doi>10.2147/IJN.S57927</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1178-2013 |
ispartof | International journal of nanomedicine, 2014, Vol.9 Suppl 2 (2), p.93-107 |
issn | 1178-2013 1176-9114 1178-2013 |
language | eng |
recordid | cdi_proquest_miscellaneous_1647009330 |
source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Dove Press Free; Free E-Journal (出版社公開部分のみ); PubMed; PubMed Central Open Access |
subjects | Administration, Oral Animals Apoptosis - drug effects Cations Edema Metal Nanoparticles - administration & dosage Metal Nanoparticles - chemistry Metal Nanoparticles - toxicity Nanoparticles Pancreas - drug effects Particle Size Physiological aspects Properties Rats Rats, Sprague-Dawley Tissue Distribution Toxicity Tests, Subchronic Zinc oxide Zinc Oxide - administration & dosage Zinc Oxide - chemistry Zinc Oxide - pharmacokinetics Zinc Oxide - toxicity |
title | A 90-day study of sub-chronic oral toxicity of 20 nm positively charged zinc oxide nanoparticles in Sprague Dawley rats |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T01%3A53%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%2090-day%20study%20of%20sub-chronic%20oral%20toxicity%20of%2020%20nm%20positively%20charged%20zinc%20oxide%20nanoparticles%20in%20Sprague%20Dawley%20rats&rft.jtitle=International%20journal%20of%20nanomedicine&rft.au=Park,%20Hark-Soo&rft.date=2014&rft.volume=9%20Suppl%202&rft.issue=2&rft.spage=93&rft.epage=107&rft.pages=93-107&rft.issn=1178-2013&rft.eissn=1178-2013&rft_id=info:doi/10.2147/IJN.S57927&rft_dat=%3Cgale_proqu%3EA401216703%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1645783293&rft_id=info:pmid/25565829&rft_galeid=A401216703&rfr_iscdi=true |